Literature DB >> 24065476

AKAP12/Gravin gene expression in colorectal cancer: clinical importance and review of the literature.

M Yildirim1, D Suren, M Yildiz, A Sezgin Alikanoglu, R Eryilmaz, S Goktas, N Bulbuller, C Sezer.   

Abstract

PURPOSE: : Colorectal cancer (CRC) is a common and potentially lethal disease. A number of genetic aberrations is known to take place in colorectal carcinogenesis, which leads to progressive alteration of normal mechanisms controlling cell growth. A-kinase-anchoring protein 12 (AKAP12) plays a role in cell proliferation, angiogenesis and cytoskeletal remodeling. The purpose of this study was to demonstrate the role of the AKAP12 gene expression in CRC patients and to determine its relationship (if any) with prognosis.
METHODS: AKAP12 gene expression was investigated by immunohistochemistry.
RESULTS: A total of 55 patients (63.6% males, 36.4% females) with histologically confirmed CRC were studied. Normal intestinal epithelium showed weak basal staining, dysplastic areas were stained mildly, whereas all of the cancer cells were stained completely with AKAP12.
CONCLUSION: AKAP12 gene seems to play a role in colorectal carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24065476

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  3 in total

1.  Evaluation of potential regulatory function of breast cancer risk locus at 6q25.1.

Authors:  Yaqiong Sun; Chuanzhong Ye; Xingyi Guo; Wanqing Wen; Jirong Long; Yu-Tang Gao; Xiao Ou Shu; Wei Zheng; Qiuyin Cai
Journal:  Carcinogenesis       Date:  2015-12-08       Impact factor: 4.944

2.  AKAP12 deficiency impairs VEGF-induced endothelial cell migration and sprouting.

Authors:  Peter M Benz; Yindi Ding; Heike Stingl; Annemarieke E Loot; Joana Zink; Ilka Wittig; Rüdiger Popp; Ingrid Fleming
Journal:  Acta Physiol (Oxf)       Date:  2019-06-21       Impact factor: 6.311

3.  Pan-cancer analysis of the prognosis and immunological role of AKAP12: A potential biomarker for resistance to anti-VEGF inhibitors.

Authors:  Qiuju Liang; Jinwu Peng; Zhijie Xu; Zhilan Li; Feng Jiang; Lingzi Ouyang; Shangjun Wu; Chencheng Fu; Ying Liu; Yuanhong Liu; Yuanliang Yan
Journal:  Front Genet       Date:  2022-08-30       Impact factor: 4.772

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.